TC BioPharm (NASDAQ:TCBP) PLC CEO Bryan Kobel tells Proactive the clinical stage biotechnology company expects to begin dosing patients with its allogeneic unmodified cell therapy in the second half of 2022 with Acute Myeloid Leukemia (AML). Kobel says data readouts should be expected in the UK next nine months, as well as expansion of the clinical study into the US.
TC BioPharm updates on its ongoing clinical study to treat patients with Acute Myeloid Leukemia
